ReviewRadiologie (Heidelberg, Germany)2026
[Pseudoprogression after start of immunotherapy].
Review in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
clinical/methodical issueDistinguishing pseudoprogression from true progression represents a considerable challenge in both clinical practice and radiological imaging. STANDARD RADIOLOGICAL
methodsEstablished radiological methods include computed tomography (CT) and magnetic resonance imaging (MRI), complemented by fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT from nuclear medicine. METHODICAL INNOVATIONS: Novel PET/CT tracers, liquid biopsies, and radiomics are considered innovative approaches that may facilitate the detection of pseudoprogression but still need clinical validation. PERFORMANCE: CT, MRI, and PET/CT can provide valuable clues for distinguishing pseudoprogression from true progression, but are often inconclusive. Novel imaging approaches are currently under investigation in clinical studies. ACHIEVEMENTS: The use of laboratory markers and radiomics has shown promising improvements in several studies, but has not yet been adopted into clinical routine. PRACTICAL RECOMMENDATIONS: In clinically stable patients, suspected pseudoprogression early after start of immunotherapy justifies continuation of therapy with close imaging follow-up (early follow-up after 4-8 weeks).
Indexed as
Identifiers
41364195What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.